Pancreatic cancer gene study targets muscle wasting

NCT ID NCT05275075

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study aimed to find genetic differences, called microRNAs, that might explain why some pancreatic cancer patients lose muscle mass (cachexia). Researchers planned to analyze tumor samples from 40 patients undergoing surgery, focusing on African Americans who may be at higher risk. The study was terminated early, so findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help identify genetic markers for cachexia, leading to earlier detection and better management of muscle wasting in pancreatic cancer patients.

What could go wrong

This was a small pilot study that ended early, so results may be limited. It only looked at tumor samples, not treatments, so it won't directly improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cachexia pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73117, United States